Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT), encouraging shareholders to contact the firm to discuss their rights [1][2]. Company Summary - The investigation focuses on whether the management of Applied Therapeutics has acted in the best interests of shareholders, which may lead to corporate governance reforms and financial recoveries for investors [1][2]. - Long-term shareholders of Applied Therapeutics may seek various forms of relief, including the return of funds to the company and court-approved financial incentives [2][3]. Legal Context - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered significant amounts for defrauded investors [4].

Oct 28, 2025 9:37 AM Eastern Daylight Time Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights Contacts Halper Sadeh LLCOne World Trade Center85th FloorNew York, NY 10007Daniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.comhttps://www.halpersadeh.com Industry: Share Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK--(BUSINESS WIRE)--Halper ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement. ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards' leadership in setting the standard for lasting valve performance and excellent patien. ...

New York, New York--(Newsfile Corp. - October 23, 2025) - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenl ...

Oct 23, 2025 7:05 AM Eastern Daylight Time Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. Contacts Media Contact: Amy Meshulam, 949-250-4009Investor Contact: Mark Wilterding, 949-250-6826 Industry: Edwards Lifesciences Corporation Share IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to a ...

Core Insights - Edwards Lifesciences Corporation (NYSE:EW) is recognized as one of the top medical device stocks to invest in, with Piper Sandler maintaining an Overweight rating and a $90 price target ahead of the PARTNER 3 study findings [1][2] Group 1: Company Overview - Edwards Lifesciences Corporation specializes in developing and selling patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for treating structural heart disease and critical care [2] Group 2: PARTNER 3 Study - The PARTNER 3 trial, which has a follow-up period of ten years, compares surgical aortic valve replacement (SAVR) with the Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients [2] - Upcoming data from the PARTNER 3 study is expected to demonstrate that TAVR is not inferior to SAVR, which may result in findings that have minimal commercial implications [2]

Core Insights - Edwards Lifesciences Corp. (EW) is set to report its third-quarter 2025 results on October 30, after market close [1][9] - The company’s adjusted earnings per share for the last quarter were 67 cents, exceeding the Zacks Consensus Estimate by 8.06%, with an average surprise of 5.50% over the past four quarters [1] Q3 Estimates - The Zacks Consensus Estimate for revenues is $1.50 billion, indicating an 11.5% growth from the previous year [2] - The earnings estimate is 59 cents per share, reflecting an 11.9% decline from the year-ago figure [2][3] Performance Factors - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform strongly in the U.S., driven by the SAPIEN 3 Ultra RESILIA platform, with projected sales of $1.11 billion, an 8.5% year-over-year increase [4][5][9] - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is anticipated to report revenues of $134.1 million, a 47.2% increase from the previous year, supported by the PASCAL repair system and the EVOQUE tricuspid replacement system [6][7][9] - The Surgical Structural Heart segment is estimated to generate revenues of $256.7 million, reflecting a 7% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [10] Earnings Expectations - Edwards has an Earnings ESP of +0.47%, indicating a higher likelihood of beating estimates [11] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [12]

Company Overview - Edwards Lifesciences Corporation, founded in 1958, is based in Irvine, CA and is a leader in designing and commercializing innovative technologies for the treatment of advanced cardiovascular diseases [1] Investment Philosophy - The investment philosophy emphasizes the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good and bad times yields the greatest rewards [1] - The approach to investing combines steady accumulation of high-quality assets with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1] Personal Background of the Investor - The investor describes themselves as an amateur investor, self-taught with no formal education in investing or business, but adept at discerning valuable insights from others [1] - The investor has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University, along with being an accomplished academic writer and editor [1]

Company Overview - Edwards Lifesciences Corporation, founded in 1958, is based in Irvine, CA, and is a leader in designing and commercializing innovative technologies for the treatment of advanced cardiovascular diseases [1]. Investment Philosophy - The investment philosophy emphasizes the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good and bad times yields the greatest rewards [1]. - The approach to wealth creation involves the slow accumulation of high-quality assets, mixed with high-risk/high-reward opportunities and transformative technologies [1]. Educational Background - The individual has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University, indicating a strong academic background [1].